trabedersen

PreclinicalRNA therapy

IIsarna Therapeutics GmbH

trabedersen is one of 50 small molecule programs targeting Newly Diagnosed. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Newly DiagnosedRecruiting

Newly DiagnosedPreclinical

Recruiting

Competition

Competitive Landscape

76 competitors in Newly Diagnosed

#DrugCompanyPhaseTrials

Venclexta

AbbVie

Phase 3

15 2

Cytosar

Teva

Phase 3

14 3

Rituxan

Roche

Phase 3

11 4

Oncovin

Eli Lilly

Phase 3

7 5

Adriamycin

Pfizer

Phase 3

6 6

Darzalex

Johnson & Johnson

Phase 3

4 7

Decadron

AAspen Global Incorporated

Phase 3

14 8

Vanflyta

Daiichi Sankyo

Phase 3

3 9

Oncovin

Eli Lilly

Phase 3

3 10

Cytoxan

BBaxter Healthcare Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

PreclinicalActive, not recruiting

Non-Small Cell Lung Cancer

NCT06579196

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

Withdrawn·UUniversity of Washington·Phase 2·NCT05935774

Evaluation of Trabedersen (OT-101) With Pembrolizumab in Patients With Newly Diagnosed Advanced Non-Small Cell Lung Cancer and Positive PD-L1

Active, not recruiting·UUniversity of Nebraska·Preclinical·NCT06579196·45 enrolled

Anaplastic Astrocytoma1 trial

Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

Terminated·IIsarna Therapeutics GmbH·Phase 3·NCT00761280·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for trabedersen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — trabedersen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for trabedersen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Isarna Therapeutics GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Preclinical[1]
Company: IIsarna Therapeutics GmbH

trabedersen

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Anaplastic Astrocytoma1 trial

References

Drug Info

Quick Facts

Related News